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Abstract
Introduction. Diabetes and obesity are diseases characterized by their increasing incidence every year. When comparing 
with healthy subjects, the serum levels of chromium (Cr) are lowered in these two diseases. Several studies conducted in 
laboratory animals with experimentally- induced diabetes demonstrated that supplementation with chromium ions (III) 
decreased glucose concentration in the blood, reduced the probability of atherosclerosis and heart attack, lowered the 
levels of cholesterol and low density lipoprotein (LDL). The Importance of chromium is actually challenged due to lack of 
clear manifestations of Cr deficiency in humans and animals.   
Objective. The aim of this review was to present current knowledge about Cr its role in the organism and possible mechanisms 
of its action also in metabolic disorders such as diabetes or obesity.   
State of knowledge. In the last decade, Cr was established to be rather a beneficial than essential trace element in mammals, 
and has gained popularity as a nutritional supplement and a component of many multivitamin/mineral formulations, 
fortified food and energy drinks. Cr supplements are widespread for diabetes and obesity treatment, despite conflicting 
reports on its efficacy. It was suggested that Cr shows a beneficial influence upon glucose and lipid disturbances.   
Conclusions. The recent clinical trials provided evidence both in favor and against the importance of Cr in healthy and 
ill organisms. Unfortunately, also the molecular mechanism by which chromium affects glucose and lipid metabolism is 
still unclear. Beneficial effects of diet supplementation with different sources of Cr3+ can be potentially explained by rather 
pharmacological than nutritional effects.
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INTRODUCTION
Chromium (Cr) is an ubiquitous metal, occurring in water, 
soil and biological systems. The three most stable forms of 
chromium occurring in the environment are: 0, +3, and +6 
valence state; metal and alloys, trivalent chromium, and 
hexavalent chromium, respectively. Trivalent chromium is 
considered to be an essential element, both in animal feeding 
and human nutrition. In late 1950s, Schwarz and Mertz 
reported that feeding rats with a Torula- yeast-based diet 
resulted in the development of impaired glucose tolerance, 
and the authors indentified Cr3+as an integral part of the 
protein recognized as glucose tolerance factor (GTF) [1]. The 
evidence on the essential Cr role in total parenteral nutrition 
(TPN) of patients has been presented [2,3]. However, a limited 
number of patients demonstrating a variety of symptoms 
and their different health status make these observations 
questionable. In animals, no symptoms of adverse effects of 
low levels of Cr in feeds have been observed. Furthermore, 
reproduction of experiments in rats fed with Torula yeast did 
not provide evidence that chromium is an essential element 
[4]. However, other authors regard chromium (III) as an 
essential trace element and/or showing beneficial effects in 
humans [5].
This trace element is involved in the metabolism of 
carbohydrates, lipids, and proteins mainly by increasing 
the efficiency of insulin. Chromium deficiency affects the 
maintenance of normal glucose tolerance and healthy lipid 
profiles. The suggestion that Cr intake is generally low has 
generated interest regarding the supposed beneficial effects 
of Cr supplementation on biological function and health 
of animals and humans. In the USA in 2001, the dietary 
guidelines for daily chromium uptake was lowered from 
50–200 for adults to 35 and 25 μg for men and women, 
respectively (Food and Nutrition Board at the Institute of 
Medicine).
This review presents current knowledge about chromium, 
its role in the organism and possible mechanisms of action. 
The role of Cr supplementation in metabolic disorders such 
as diabetes and obesity, as well as in healthy organisms, is 
discussed.
Absorption, bio-distribution and excretion. Chromium is 
absorbed together with other metal ions in the gut through 
the unsaturated passive transport [6]. The efficiency of this 
process is very low with the average absorption ranging from 
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0.4 – 2.5% [7]. The absorption process depends on the Cr 
content in the diet and on the chemical form of this element 
and other food components. Studies conducted in rats showed 
increased absorption of Cr used in the form of nicotinate 
(1.3%) and picolinate (1.1%) in comparison to chromium 
chloride (0.9%) [8]. It was shown that absorption of Cr in 
humans in the form of chromium chloride is much lower 
(0.1–0.4%) than of chromium picolinate (2.8%) or chromium 
given as the yeast chromium (5–10%) [7,9]. Organic sources of 
Cr (i.e. picolinate, or propionate-methionine salt) are much 
better absorbed than inorganic forms (e.g. oxides), and lead 
to the increase of these compounds concentration in tissues 
[10]. The highest dose-accumulation correlation of Cr in the 
tissues is observed after administration of Cr nanoparticles 
[11,12]. However, other factors present in the diet show a 
significant impact on the amounts of Cr absorbed from the 
gastrointestinal tract. Starch, simple sugars, ascorbic acid, 
oxalic acid, nicotinic acid, some amino acids, aspirin increase 
absorption of this element [13–16], while high concentrations 
of phosphate, calcium, magnesium, titanium, zinc, vanadium 
and iron reduce the rate of this process [13,17].
After absorption from the intestine, chromium (III) is 
released into the bloodstream where it is bound by proteins 
involved in iron metabolism. In vitro and in vivo studies in 
rats have shown that about 80% Cr in the blood is associated 
with transferrin [18]. In this complex, Cr is transported to 
the cells, and the efficiency of Cr transfer through the cell 
membrane depends on insulin concentration [19].
Chromium is found in all animal tissues and is present 
at the concentrations of several to tens of µg/kg, rarely 
exceeding 100 µg/kg [20]. The highest concentrations are 
found in the liver, kidneys and spleen, while slightly lower 
levels are observed in heart, muscle, pancreas, lungs, bones 
and brain [21, 22]. It has been shown that certain tissues, such 
as bones, testis and epididymis, are capable of storing CR in a 
long-term manner, in comparison to heart, pancreas or brain, 
where the turnover of chromium ions is relatively short [23].
Supplementation with chromium ions in livestock 
reveals differences in the accumulation of this element in 
the tissues. In pigs, feed enrichment with 0.2 mg of Cr/kg 
caused its accumulation in the liver and kidneys, with no 
clear impact on the concentration in the muscle, while in 
cattle, no significant changes of Cr levels in the tissues and 
major organs were observed [24]. Studies in poultry revealed 
that Cr administration in various forms (yeast, chromium, 
picolinate, chromium chloride) cause accumulation of this 
element in the liver, kidneys and muscles, without significant 
differences found for the eggs of hens [25, 26].
More than 80% of Cr is removed from the body in the form 
of urine, while the remaining part of this element is excreted 
via faeces and sweat [27]. In humans, consumption of large 
amounts of sugar, exhaustive physical exercise, pregnancy 
and lactation leads to increased Cr excretion in the urine [28]. 
Negative Cr balance was observed in patients suffering from 
diabetes type 1 [29]; enhanced secretion of this element in 
the urine was also found in rats after intramuscular injection 
of insulin [30].
The role of chromium in the body. The first information 
in the literature suggesting a biological role for chromium 
appeared in the late 1950s [1], while in 1996, Cr was considered 
as a trace element necessary for proper functioning of 
living organisms [31]. Currently, the essential role of Cr is 
questioned, mainly due to the lack of clear manifestations 
of Cr deficiency in mammals [4, 32]. It has been suggested 
that Cr should be classified as a factor nutritionally or 
pharmacologically beneficial [33, 34].
Chromium III is involved in many different processes 
including sugar and lipids metabolism. In the studies 
conducted in cattle and rats, diet supplementation with high 
amounts of Cr decreased the levels of total cholesterol, LDL-
cholesterol, triglycerides and non-esterified fatty acids; the 
increased levels of HDL-cholesterol and the beta-oxidation 
process were also observed [35–38]. Similar properties of 
Cr were noticed in experiments with murine myogenic 
C2C12 cell lines [39]. Supplementation with chromium 
ions (III) (above 1 mg/kg body weight) also caused a dose-
dependent reduction in serum leptin concentrations in rats. A 
similar trend was observed in human studies [35, 40]. It was 
shown that Cr supplementation increased the rate of amino 
acids transport into the cells. In the study by Lindeman 
et al. in 2007, a trend to decrease serum level of a stress 
hormone – cortisol, was noticed, however, without a clear 
correlation between these two factors [41]. Chromium can 
affect biological effects induced also by other trace elements. 
The common transport mechanism for chromium and 
iron makes these metals compete for the binding site of 
transferrin. In rats treated intraperitoneally with chromium 
ions, reduction in the bioavailability of iron in the body, 
with the onset of symptoms characteristic of anaemia, was 
observed [42]. It was shown that oral administration of Cr 
(as chromium nitrate) counteracts the effects of the selenium 
anti-carcinogenic mechanisms in the growth and latency 
of murine mammary tumour induced by the MMTV virus 
[43]. Chromium is engaged in the proper functioning of the 
immune system [44]. The use of Cr to both in vivo and in 
vitro studies modified the levels of several cytokines: IL-1, 
IL-2, IL-6, IFN and TNF-α [45, 46]. It was suggested that a 
nutrigenomic study may shed more light on the mechanisms 
of Cr-gene interaction, and provide a better understanding 
of the chromium mode of action [47].
Possible mechanism of action. Despite numerous studies, 
there is no clear explanation how chromium ions influence 
carbohydrate and lipid metabolism. There are several theories 
which explain chromium impact on the glucose metabolism. 
Among these, the most widely accepted hypothesis is the 
involvement of an oligopeptide, named chromodulin 
(LMWCr, a low-molecular weight chromium-binding 
substance) [48, 49]. LMWCr is a small peptide with a mass 
of about 1,500 kDa, built only of amino acids: 2 glycine, 2 
cysteine, 4 glutamic acid and 2 molecules of aspartic acid [50]. 
It has an ability to bind four chromium atoms, and only in 
this form it shows its full biological activity [51]. Vincent et al. 
(1999) explained the mechanisms of chromium ions uptake 
and insulin receptor kinase activation by chromodulin [52]. 
According to the proposed mechanism, LMWCr is present 
in the cytoplasm and nucleus of the cells sensitive to insulin 
in an inactive form called ‘apochromodulin’. Upon insulin 
binding, the transferrin receptor is activated, which further 
leads to internalization of transferrin-chromium complex 
into the cell. Internalization of this complex causes activation 
of the ATP-dependent proton pump, decrease of pH, release 
of Cr from transferrin and its binding by chromodulin. After 
binding of four chromium atoms, a chromodulin molecule is 
converted into a biologically-active ‘holochromodulin’ which 
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binds to the insulin receptor beta subunit, previously activated 
by the hormone, resulting in activation of receptor tyrosine 
kinase and insulin signal amplification. As a result, activation 
of the intracellular insulin signal transduction system leads 
to the co-localization of GLUT4 protein (glucose transporter 
protein 4) to the cell membrane. GLUT4 is the principal 
glucose transporter mediating glucose transport through 
the cell membrane [53]. However, the exact structure of 
LMWCr remains unknown. New information concerning the 
sequence of this oligopeptide and Cr binding properties has 
been recently provided by Chen et al, 2011 [54]. However, the 
experiments with Cr supplementation can be also interpreted 
as a result of non-specific binding of Cr to the amino acid 
sequences. These types of proteins were found in rat liver 
(9 proteins with a molecular weight from 4 – 97 kDa) and 
bovine liver (15.6 kDa) [18,55]. Furthermore, chromodulin 
activity stimulating the insulin receptor tyrosine kinase is 
unspecific. It was observed that activation of tyrosine kinase 
by insulin may be also caused by other metal ions, such as 
zinc, manganese, cadmium and certain xenobiotics, e.g. 
metformin and pioglitazone [56].
Another theory about the role of Cr in glucose metabolism 
indicates for a direct insulin receptor activation by 
chromium ions. Balamurugan et al. [57] showed that high 
levels of chromium caused induction of ROS synthesis in 
lymphocytes. A similar effect for the myogenic C2C12 cell 
line was observed. Chromium increased ROS synthesis 
(about 400% of initial ROS concentration) after 1 min. of 
administration, then cyclic decreases and increases were 
observed with a similar effect to insulin administration. This 
effect was due to the changes in the membrane phosphatases 
activity. The authors suggest that ROS are essential and 
necessary for the optimal metabolic effect of chromium ions.
One of the new concepts of Cr action was proposed by 
Pattar, et al [58] who formulated a hypothesis that chromium 
ions affect the membrane fluidity and thereby regulate the 
uptake of glucose by the cells. This effect was associated with 
the reduced cholesterol content in the cell membrane, which 
is considered a factor lowering glucose transport controlled 
by the insulin receptor. In addition, these authors showed 
no effect of chromium ions on the phosphorylation of the 
insulin signal transduction proteins: IR-beta, IRS, PI 3-K 
and Akt-1. Results a study Raja et al. showed the ability of 
Cr to interact and modify the structure of lipid bilayers [59].
It is also possible that the mode of action of Cr depends on 
activation of the estrogen receptor. It is assumed that estrogen 
may act through two signaling pathways: insulin receptor-
dependent (IR) and the receptor for insulin-like growth 
factor (IGF-1) -dependent [60]. It has been shown that Cr is 
a metal possessing estrogenic properties and it can stimulate 
transcription of genes in cells containing estrogen receptor 
[61, 62]. Molecular mechanism of estrogen influence on 
insulin-stimulated processes is not fully recognized. It can be 
divided into two parts: a fast signal (related with membrane 
estrogen receptors activation) and a slow signal (related with 
nucleus estrogen receptors activation). Some new evidence 
on the chromium estrogenic properties is provide in the 
doctoral dissertation by Lewicki [63]. The microarray profiles 
of Cr and estrogen treated C2C12 cells (mouse myocytes) 
were almost similar. It was observed that out of 24 genes, 
the expression of which was altered by supplementation with 
chromium ions Cr3+ 10 ug/L, 19 genes were common with 
those that were estradiol-induced (10 nM).
Chromium in diabetes and obesity. Diabetes and obesity 
are diseases of the most serious public health concern. It is 
estimated that each year the number of new patients with 
diabetes increases by millions of people (700,000 in the 
USA, 110,000,000 in Asia), while obesity is a problem for 
more than 15% of Europeans and 20% of North Americans 
[64–66]. Treatment of the symptoms and complications 
of diabetes worldwide consume huge funds; only in USA, 
billions of dollars are allocated yearly for this purpose [67]. 
In both cases, serum levels of Cr are lower, compared with 
healthy individuals [68, 69]. Since chromium (III) modulates 
insulin action and glucose homeostasis, diabetes and obesity 
are logical candidates for Cr replacement therapy. Positive 
outcomes of Cr supplementation included reduction in 
the used hypoglycaemic medication and decrease in 
glucose concentration, cholesterol and triglyceride in the 
blood. However, the results of different studies are often 
contradictory.
Several studies conducted in laboratory animals with 
experimentally-induced diabetes, demonstrated that 
supplementation with chromium ions (III) decreased glucose 
concentration in the blood, reduced the probability of 
atherosclerosis and heart attack, as well as lowered cholesterol 
and low density lipoprotein – LDL [70, 71, 72]. It has been 
suggested [73, 74, 75] that Cr concentration  increases 
phosphorylation of enzymes associated with the post-
receptor insulin signaling: IR, IRS1, GDP and PKCζ (p-IRTyr, 
p-IRS1Tyr, p-PKBSer, p-PKCζThr). Animals consuming a 
chromium-enriched diet were tested for tolerance to oral 
administration of glucose (OGT), and showed a faster 
metabolism of glucose, compared to those which were 
treated with a low Cr diet. In human with diabetes 2, Cr 
supplementation can improve glucose metabolism and insulin 
action [76, 77, 78]. A similar effect was shown in patients 
with severe insulin resistance, who were given i.v. infusion 
of chromium (III) [79, 80]. Based on the own study results, 
Jain et al. (2012) [81] concluded that Cr supplementation has 
a potential as an adjunct therapy for patients suffering from 
type 2 diabetes. Interestingly, Cefalu et al. [82] observed that 
a consistent effect of Cr action in subjects with type 2 diabetes 
may be related with their genetic phenotype.
There are also several publications describing a positive 
role of Cr in the reduction of lipids content and body mass 
in obese humans and animals [70, 83, 84]. However, other 
studies showed lack of Cr protective function in metabolic 
syndrome observed for obese but non-diabetic adults [85].
Unfortunately, there are only a few studies concerning 
the effect of Cr supplementation on the metabolism of 
carbohydrates and lipids levels in healthy individuals. These 
studies are mostly a guesswork. A systematic review of 
randomized controlled trials evaluating Cr supplementation 
showed lack of beneficial effects in healthy individuals 
[86,87]. In studies with a controlled energy intake, no 
decrease in body weight in Cr supplemented (200 μg Cr/d) 
subjects was observed [88, 89]. Despite the high popularity 
of Cr supplementation, it seems that it is not effective in 
producing a sustained weight loss. However, it was shown for 
overweight or obese patients that a long-term use of vitamins 
B6 and B12 and Cr were significantly associated with a lower 
weight gain [90].
In non-obese, non-diabetic subjects, Cr therapy was 
shown not only to have no effect on the insulin sensitivity 
improvement, but it paradoxically declined its sensitivity [91].
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CONCLUSIONS
Many report have shown that chromium III ions have 
beneficial properties for the organism with disturbances 
of glucose or lipids metabolism. However, data from the 
experiments conducted in healthy individuals quite often 
explicitly show lack of any favourable impact of chromium on 
sugar/lipids metabolism. This in turn leads to the hypothesis 
that chromium ions supplementations have been beneficial 
only in ‘disordered organisms’. For the other roles of 
chromium in the body, we should use this supplement in a 
reasonable manner, being aware of its possible side-effects.
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